Dr. Tudor Oprea, CSO of Expert Systems Inc (San Diego, CA) and Dr. Ruben Abagyan, Co-founder and Chief Scientific Advisor of Expert Systems, Founder and CEO of Molsoft LLC, Professor at Skaggs School of Pharmacy and Pharmaceutical Sciences, UC San Diego, presented at “Artificial Intelligence for Early Drug Discovery” Conference in San Diego, CA on April 11-12, 2023.
Dr. Ruben Abagyan presented at the event with a discussion on “Giga-Screening for Preclinical Candidates with a Defined Multi-Target Profile”, where he explored the challenges of rapid identification of first-in-class or best-in-class preclinical drug candidates, illustrating the topic with examples of Eilean Therapeutics’ program for “tough” targets such as FLT3 and BCL2. Rational design by Molsoft team has led to discovery and development of best-in-class candidates initiating clinical studies in primary and drug resistant leukemias and lymphomas within 2 years from the program inception.
Dr. Tudor Oprea discussed advances in computer science and bioinformatics in his presentation: “Can Humans Learn from Machine Learning in Drug Discovery?” focusing on the success of Molsoft and Expert Systems design teams in ultra- efficient discovery and development of the best-in-class M-Pro/3CL candidate, for which clinical trials to treat COVID-19 are being initiated.
Eilean Therapeutics LLC is targeting escape mutations in hematological cancers with first and best in class medicines. It has been funded by i2020 Accelerator and OrbiMed Advisors and utilizes world’s best rational design and virtual discovery and development platforms as well as an arsenal of unique chemistry and biology tools to address highly valuable cancer targets.
Expert Systems Inc is a consulting platform for drug discovery and development program selection, prioritization, design, execution and market positioning. Expert Systems offers highly customized and complete solutions for pharma and biotech in oncology, inflammation, immunology, cardiometabolic, neurology and infectious disease therapeutic areas.
Molsoft LLC is a leading provider of tools, databases and consulting services in the areas of structure prediction, structural proteomics, bioinformatics, cheminformatics, molecular visualization and animation, and rational drug design. Molsoft offers complete solutions customized for a biotechnology or a pharmaceutical company in the areas of computational biology and chemistry. Molsoft is committed to continuous innovation, scientific excellence, the development of the cutting-edge technologies and original ideas.
About i2020 Accelerator
i2020 Accelerator strives to accelerate early-stage drug discovery platforms towards advanced lead and clinical candidates within a two-year framework to rapidly de-risk novel science and enrich partner pipelines with first or best-in-class molecules. i2020's scientific and global resources network tailored specifically to the needs of early programs allows to accelerate development in multiple high value therapeutic areas, from immunology to inflammation and from oncology and CNS to infectious diseases and beyond. The i2020 accelerator program inaugurated by Torrey Pines Investment in 2017 is now co-creating, growing and graduating breakthrough drug discovery programs towards future medicines.